Trevi Therapeutics, Inc.

TRVINASDAQHealthcareBiotechnology

$12.51- (-)1Y +21.50%

As of Oct 26, 2026 close

Market cap: $1.96B
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $9.82$20.22
Volume (live): -
Avg. volume (3M): 2.48M

Trevi Therapeutics, Inc. (TRVI) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Trevi Therapeutics, Inc. stock.

Analyst Consensus Rating

Investment consensus from 10 professional research analysts

Consensus Rating

Buy

Based on 10 unique analysts

(12 total ratings in last 90 days)

High Confidence∞:1 Buy/Sell

Average Price Target

$29.00

+131.81% upside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest TRVI Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 22, 2026	Debanjana Chatterjee	JonesTrading	Maintains	Buy	$28.00
Oct 7, 2026	Conor MacKay	BMO Capital	Maintains	Buy	$36.00
Sep 21, 2026	Brandon Folkes	HC Wainwright	Maintains	Buy	$24.00
Aug 13, 2026	Debanjana Chatterjee	JonesTrading	Reiterates	Buy	$24.00 → $28.00 +4.00 (+16.7%)
Aug 10, 2026	Judah Frommer	Morgan Stanley	Reiterates	Buy	$23.00
Aug 7, 2026	Annabel Samimy	Stifel Nicolaus	Reiterates	Buy	$30.00
Aug 7, 2026	Joshua Schimmer	Cantor Fitzgerald	Reiterates	Buy	$25.00 → $30.00 +5.00 (+20.0%)
Aug 7, 2026	Leland Gershell	Oppenheimer	Reiterates	Buy	$24.00 → $25.00 +1.00 (+4.2%)
Aug 7, 2026	Ryan Deschner	Raymond James	Maintains	Buy	$40.00
Aug 7, 2026	Mayank Mamtani	B Riley	Initiates	Buy	$31.00
Aug 7, 2026	Serge Belanger	Needham	Maintains	Buy	$23.00
Aug 6, 2026	Joshua Schimmer	Cantor Fitzgerald	Reiterates	Buy	$25.00 → $30.00 +5.00 (+20.0%)

Debanjana Chatterjee

JonesTrading

BuyMaintains

$28.00

Oct 22

Conor MacKay

BMO Capital

BuyMaintains

$36.00

Oct 7

Brandon Folkes

HC Wainwright

BuyMaintains

$24.00

Sep 21

Debanjana Chatterjee

JonesTrading

BuyReiterates

$24.00 → $28.00

Aug 13

Judah Frommer

Morgan Stanley

BuyReiterates

$23.00

Aug 10

Annabel Samimy

Stifel Nicolaus

BuyReiterates

$30.00

Aug 7

Joshua Schimmer

Cantor Fitzgerald

BuyReiterates

$25.00 → $30.00

Aug 7

Leland Gershell

Oppenheimer

BuyReiterates

$24.00 → $25.00

Aug 7

Ryan Deschner

Raymond James

BuyMaintains

$40.00

Aug 7

Mayank Mamtani

B Riley

BuyInitiates

$31.00

Aug 7

Serge Belanger

Needham

BuyMaintains

$23.00

Aug 7

Joshua Schimmer

Cantor Fitzgerald

BuyReiterates

$25.00 → $30.00

Aug 6

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 22, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for TRVI?

The analyst consensus rating for TRVI is Buy, based on the latest ratings from 10 analysts over the last 90 days.

What is the average price target for TRVI?

The average 12-month price target for TRVI is $29.00, representing an upside of 131.8% from the Oct 26, 2026 close of $12.51.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.